Oppenheimer restated their hold rating on shares of Axovant Sciences (NASDAQ:AXON) in a research report report published on Sunday morning.

AXON has been the topic of several other research reports. Zacks Investment Research upgraded shares of Axovant Sciences from a hold rating to a buy rating and set a $2.25 target price on the stock in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Axovant Sciences from a strong sell rating to a sell rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Axovant Sciences from a hold rating to a buy rating in a research note on Thursday, November 1st. Cowen restated a hold rating on shares of Axovant Sciences in a research report on Thursday, September 20th. Finally, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Axovant Sciences in a research report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $4.56.

Shares of NASDAQ AXON opened at $1.95 on Friday. Axovant Sciences has a 52-week low of $1.02 and a 52-week high of $6.59. The company has a debt-to-equity ratio of 1.68, a quick ratio of 1.97 and a current ratio of 1.97.

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in Axovant Sciences by 60.5% during the third quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock valued at $5,062,000 after purchasing an additional 788,100 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock valued at $1,354,000 after purchasing an additional 64,152 shares during the period. BlackRock Inc. lifted its position in Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock valued at $3,447,000 after purchasing an additional 169,918 shares during the period. Tower Research Capital LLC TRC lifted its position in Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the period. Finally, Paloma Partners Management Co bought a new position in Axovant Sciences during the second quarter valued at approximately $356,000. Institutional investors own 9.31% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Recommended Story: How Short Selling Works

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.